These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 1893642)
1. The pharmacokinetics of benazepril relative to other ACE inhibitors. Gengo FM; Brady E Clin Cardiol; 1991 Aug; 14(8 Suppl 4):IV44-50; discussion IV51-5. PubMed ID: 1893642 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic/pharmacodynamic modeling of benazepril and benazeprilat after administration of intravenous and oral doses of benazepril in healthy horses. Serrano-Rodríguez JM; Gómez-Díez M; Esgueva M; Castejón-Riber C; Mena-Bravo A; Priego-Capote F; Ayala N; Caballero JMS; Muñoz A Res Vet Sci; 2017 Oct; 114():117-122. PubMed ID: 28371693 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs. King JN; Mauron C; Kaiser G Am J Vet Res; 1995 Dec; 56(12):1620-8. PubMed ID: 8599524 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog. King JN; Maurer M; Morrison CA; Mauron C; Kaiser G Xenobiotica; 1997 Aug; 27(8):819-29. PubMed ID: 9293618 [TBL] [Abstract][Full Text] [Related]
5. The influence of hepatic cirrhosis on the pharmacokinetics of benazepril hydrochloride. Kaiser G; Ackermann R; Gschwind HP; James IM; Sprengers D; McIntyre N; Defalco A; Holmes IB Biopharm Drug Dispos; 1990 Dec; 11(9):753-64. PubMed ID: 2271751 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats. King JN; Maurer M; Toutain PL J Vet Pharmacol Ther; 2003 Jun; 26(3):213-24. PubMed ID: 12755906 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of the ace inhibitor benazepril hydrochloride in the elderly. Kaiser G; Ackermann R; Dieterle W; Durnin CJ; McEwen J; Ghose K; Richens A; Holmes IB Eur J Clin Pharmacol; 1990; 38(4):379-85. PubMed ID: 2344861 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of benazepril hydrochloride in patients with major proteinuria. Schweizer C; Kaiser G; Dieterle W; Mann J Eur J Clin Pharmacol; 1993; 44(5):463-6. PubMed ID: 8359184 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of a new angiotensin-converting enzyme inhibitor, benazepril hydrochloride, in special populations. Kaiser G; Ackermann R; Sioufi A Am Heart J; 1989 Mar; 117(3):746-51. PubMed ID: 2919553 [TBL] [Abstract][Full Text] [Related]
10. Plasma concentrations of an angiotensin-converting enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, after repeated administrations of benazepril in dogs with experimental kidney impairment. Kitagawa H; Eguchi T; Kitoh K; Ohba Y; Kondo M; Nakano M; Sasaki Y J Vet Med Sci; 2000 Feb; 62(2):179-85. PubMed ID: 10720188 [TBL] [Abstract][Full Text] [Related]
11. The disposition of [14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose. Waldmeier F; Kaiser G; Ackermann R; Faigle JW; Wagner J; Barner A; Lasseter KC Xenobiotica; 1991 Feb; 21(2):251-61. PubMed ID: 2058180 [TBL] [Abstract][Full Text] [Related]
12. Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach. Toutain PL; Lefebvre HP; King JN J Pharmacol Exp Ther; 2000 Mar; 292(3):1087-93. PubMed ID: 10688627 [TBL] [Abstract][Full Text] [Related]
13. Plasma angiotensin converting enzyme activity and pharmacokinetics of benazepril and benazeprilat in cats after single and repeated oral administration of benazepril.HCl. King JN; Humbert-Droz E; Maurer M J Vet Pharmacol Ther; 1999 Dec; 22(6):360-7. PubMed ID: 10651464 [TBL] [Abstract][Full Text] [Related]
14. Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. Balfour JA; Goa KL Drugs; 1991 Sep; 42(3):511-39. PubMed ID: 1720384 [TBL] [Abstract][Full Text] [Related]
15. Effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of benazepril in cats. King JN; Strehlau G; Wernsing J; Brown SA J Vet Pharmacol Ther; 2002 Oct; 25(5):371-8. PubMed ID: 12423228 [TBL] [Abstract][Full Text] [Related]
16. New insights on effect of kidney insufficiency on disposition of angiotensin-converting enzyme inhibitors: case of enalapril and benazepril in dogs. Toutain PL; Lefebvre HP; Laroute V J Pharmacol Exp Ther; 2000 Mar; 292(3):1094-103. PubMed ID: 10688628 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril.HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration. Kaiser G; Ackermann R; Brechbühler S; Dieterle W Biopharm Drug Dispos; 1989; 10(4):365-76. PubMed ID: 2758102 [TBL] [Abstract][Full Text] [Related]
18. An angiotensin converting enzyme inhibitor, benazepril can be transformed to an active metabolite, benazeprilat, by the liver of dogs with ascitic pulmonary heartworm disease. Kitagawa H; Ohba Y; Kuwahara Y; Ohne R; Kondo M; Nakano M; Sasaki Y; Kitoh K J Vet Med Sci; 2003 Jun; 65(6):701-6. PubMed ID: 12867730 [TBL] [Abstract][Full Text] [Related]
19. The absence of a pharmacokinetic interaction between aspirin and the angiotensin-converting enzyme inhibitor benazepril in healthy volunteers. Sioufi A; Pommier F; Gauducheau N; Godbillon J; Choi L; John V Biopharm Drug Dispos; 1994 Aug; 15(6):451-61. PubMed ID: 7993983 [TBL] [Abstract][Full Text] [Related]
20. Antihypertensive mechanism of action of the novel angiotensin converting enzyme inhibitor benazepril. Effect on isolated vascular preparations. Kuroda K; Fukuda Y; Nakao K; Inukai T Arzneimittelforschung; 1990 Sep; 40(9):968-73. PubMed ID: 2080946 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]